As anticipated, the European Fee approves Blueprint Medicines’ (BPMC -0.7%) Ayvakyt (avapritinib) as monotherapy for the therapy of grownup sufferers with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived development issue receptor alpha (PDGFRA) D842V mutation.

Two months in the past, the advisory group CHMP adopted a positive opinion backing approval.

Quant ranking is Bullish.

LEAVE A REPLY

Please enter your comment!
Please enter your name here